Background

Bladder cancer is a representative urological malignancy with high global incidence. While controllable in the early stages through transurethral resection or local drug instillation, the 5-year survival rate plummets below 10% once cancer cells penetrate the muscular layer and spread to distant organs. Despite the administration of platinum-based chemotherapy, immune checkpoint inhibitors, and the latest Antibody-Drug Conjugates (ADCs), most patients eventually encounter the barrier of drug resistance.

At the core of this difficulty lies extreme genetic heterogeneity and histological variation within the tumor. Cancer cells accumulate mutations while enduring therapeutic pressure, eventually transforming into highly malignant subtypes, such as those resembling neuroendocrine tumors or sarcomas. Tracking such spatiotemporal changes while the patient was alive was practically impossible. It would have been too risky to invasively biopsy each of the multiple metastatic sites disseminated throughout the body due to the high risk of bleeding and complications. It was difficult to fully map the mutational landscape of systemic cancer cells with only small amounts of tissue isolated from a single lesion, and the final evolutionary patterns of tumors occurring until just before death had long been obscured by time.

Key Findings

To break these long-standing limitations, researchers from the Fred Hutchinson Cancer Center and the University of Washington launched a systematic Rapid Autopsy Program (RAP). This technique preserves high-quality genomic information by collecting tissue samples from systemic organs within the golden hour immediately following a patient's death. The research team obtained a total of 104 tumor tissue specimens from multiple metastatic sites of 20 patients who died of end-stage metastatic bladder cancer and performed whole-exome and transcriptome analysis.

The analysis revealed that the systemic spread of metastatic cancer takes a form that completely overturns long-held hypotheses. Instead of each metastatic lesion spreading independently from the primary tumor, a specific metastatic lesion that settled first functioned as the central origin for systemic dissemination. The early-established metastatic tumor acted as a 'staging point,' re-spreading cancer cells to other organs. The phenomenon of 'metastasis-to-metastasis seeding,' in which cancer cells spread from one metastatic lesion to another, was clearly demonstrated by a distinct genetic phylogenetic tree.

The evolutionary pathway of resistance following histological subtype transformation was also clearly observed. Tumors that began as typical urothelial carcinomas underwent transformations into lethal subtypes, such as neuroendocrine types, through specific gene deletions under therapeutic pressure. In this process, existing target proteins are lost and alternative bypass pathways are activated, rendering existing drugs ineffective. The researchers also identified that information regarding such malignant subtype transformations and clonal evolution is fully reflected in the circulating tumor DNA (ctDNA) within the patient's blood. This achievement provides a clue to early detection of the emergence of lethal cancer cells through blood analysis alone, without the need for invasive biopsies.

Significance and Outlook

This achievement demonstrates that RAP specimens, made possible by the generous donations of patients, can serve as a critical stepping stone for advancing our understanding of tumor evolution. It reconstructs the comprehensive profile of systemic multiple metastatic tumors, which are difficult to obtain from living patients, and completes an integrated map of the trajectory of acquired therapeutic resistance over time. The elucidation of the mechanism by which a metastatic lesion itself serves as a source for new metastases is expected to provide strong evidence supporting the rationale for local radiotherapy or early resection in the treatment of patients with oligometastatic disease.

It also opens a path for non-invasive monitoring of not only genomic mutations but also histological subtype changes via blood ctDNA analysis. However, because the study was limited to 20 patients, additional validation is needed to generalize the characteristics of all rare variant subtypes. Future key tasks include establishing multi-center follow-up cohorts including larger patient groups and identifying the molecular weaknesses of specific resistant clones that do not respond to ADCs or immunotherapy.